- Home
- KROS vs ORIC Comparison
KROS vs ORIC Comparison
Compare KROS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 783.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KROS | ORIC |
|---|---|---|
| Price | $21.01 | $8.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $22.20 | $19.50 |
| AVG Volume (30 Days) | 790.2K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | N/A |
| Revenue This Year | $6,924.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $3.90 |
| 52 Week High | $22.55 | $14.93 |
Technical Indicators
Market Signals| Indicator | KROS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 27.80 |
| Support Level | $19.76 | $7.98 |
| Resistance Level | $21.76 | $8.62 |
| Average True Range (ATR) | 0.82 | 0.59 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 46.59 | 6.52 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.